<DOC>
	<DOCNO>NCT00735904</DOCNO>
	<brief_summary>This study evaluate whether AG-013736 combine cisplatin gemcitabine show activity safe patient squamous type non-small cell lung cancer</brief_summary>
	<brief_title>Trial Of AG-013736 , Cisplatin , And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis squamous NSCLC Stage IIIB malignant effusion ( fluid cytology demonstrate malignant cell require ) , Stage IV , recurrent disease definitive local therapy Candidate primary treatment cisplatin gemcitabine Presence measurable disease RECIST Adequate organ function define follow criterion : ECOG performance status 0 1 Prior systemic treatment Stage IIIB ( malignant effusion ) Stage IV NSCLC . One lung lesion cavitation , lesion invade abut major blood vessel assess CT MRI . History hemoptysis &gt; Â½ tsp ( 2.5 ml ) blood per day day within 1 week study treatment , Grade 3 4 hemoptysis within 4 week study treatment NCI CTCAE Grade 3 hemorrhage cause within 4 week study treatment Preexisting uncontrolled hypertension document 2 baseline blood pressure read take least 1 hour apart . Untreated brain metastasis . Need therapeutic anticoagulation , regular use aspirin ( &gt; 325 mg/day ) , NSAID medication know inhibit platelet function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>AG-013736</keyword>
	<keyword>axitinib</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>NSCLC</keyword>
	<keyword>squamous cell</keyword>
	<keyword>lung cancer</keyword>
</DOC>